Search results for "embolism"

showing 10 items of 457 documents

Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: Prospective results from a multi-center study

2021

Background Thrombosis and pulmonary embolism appear to be major causes of mortality in hospitalized coronavirus disease 2019 (COVID-19) patients. However, few studies have focused on the incidence of venous thromboembolism (VTE) after hospitalization for COVID-19. Methods In this multi-center study, we followed 1529 COVID-19 patients for at least 45 days after hospital discharge, who underwent routine telephone follow-up. In case of signs or symptoms of pulmonary embolism (PE) or deep vein thrombosis (DVT), they were invited for an in-hospital visit with a pulmonologist. The primary outcome was symptomatic VTE within 45 days of hospital discharge. Results Of 1529 COVID-19 patients discharge…

AdultMaleARDSmedicine.medical_specialtyTime FactorsDeep veinIran030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRisk FactorsFull Length ArticleInternal medicinemedicineHumansProspective Studiescardiovascular diseasesMyocardial infarctionThromboprophylaxisStrokeAgedAged 80 and overVenous Thrombosisbusiness.industryIncidenceIncidence (epidemiology)COVID-19Venous ThromboembolismHematologyMiddle Agedmedicine.diseaseThrombosisPatient DischargePulmonary embolismHospitalizationmedicine.anatomical_structure030220 oncology & carcinogenesisHeart failureFemaleCohort studyPulmonary EmbolismbusinessThrombosis Research
researchProduct

Increased risk for venous thrombosis in carriers of the prothrombin G→A20210 gene variant

1998

A mutation in the prothrombin gene (G--A20210) has been associated with higher plasma prothrombin levels and an increased tendency for venous thrombosis.To determine whether the prothrombin A20210 allele is independently associated with the occurrence of venous thrombosis.Case-control study.Two thrombosis centers in southern Italy.281 consecutive patients with venous thrombosis confirmed by objective tests and 850 controls.Medical history was collected on standardized questionnaires. The presence of prothrombin G--A2020 and factor V Leiden mutations was determined by polymerase chain reaction. The presence of anticoagulant factors and prothrombin activity was determined by tests of function…

AdultMaleHeterozygotePathologymedicine.medical_specialtyAdolescentStatistics as TopicGastroenterologyRisk FactorsSurveys and Questionnaireshemic and lymphatic diseasesInternal medicineBlood plasmaInternal MedicinemedicineFactor V LeidenHumansPoint MutationRisk factorChildVeinAllelesAgedAged 80 and overbusiness.industryVascular diseaseFactor VGeneral MedicineMiddle AgedThrombophlebitismedicine.diseaseThrombosisPulmonary embolismVenous thrombosismedicine.anatomical_structureCase-Control StudiesChild PreschoolMutationFemaleProthrombinbusinesscirculatory and respiratory physiology
researchProduct

Leisure-time cross-country skiing and the risk of venous thromboembolism: A prospective cohort study

2020

[No abstract]

medicine.medical_specialtyCross countryEpidemiologybusiness.industryLeisure timeEmergency medicineMedicineCardiology and Cardiovascular MedicineProspective cohort studybusinessVenous thromboembolismEuropean Journal of Preventive Cardiology
researchProduct

Alterations of regional cerebral blood flow and oxygen saturation in a rat sinus-vein thrombosis model.

1996

Background and Purpose The pathophysiology of sinus-vein thrombosis (SVT) in patients and experimental animals is still poorly understood. This study was designed to examine and further elucidate the pathophysiological sequence of events, especially the relationship between local and regional blood flow and hemoglobin oxygen saturation (HbSO 2 ) detected at identical locations. The use of both parameters as outcome indicators should be compared. Methods SVT was induced by ligation of the superior sagittal sinus (SSS) and slow injection of kaolin-cephalin suspension into the SSS in rats. Regional cerebral blood flow (rCBF) was assessed by laser-Doppler flowmetry together with regional HbSO …

Cerebral veinsMalemedicine.medical_specialtyPathologyTime FactorsUltrasonography Doppler TranscranialHemodynamicsMicrocirculationHemoglobinsInternal medicinemedicineAnimalsHumansFluorescein AngiographyRats WistarAdvanced and Specialized NursingCerebral Cortexbusiness.industryBrainBlood flowIntracranial Embolism and Thrombosismedicine.diseaseThrombosisCerebral VeinsRatsSSS*OxygenDisease Models AnimalCerebral blood flowOrgan SpecificityRegional Blood FlowCerebrovascular CirculationCardiologyNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessSuperior sagittal sinusStroke
researchProduct

Survival Benefit of Obese Patients With Pulmonary Embolism.

2018

To investigate the impact of obesity and underweight on adverse in-hospital outcomes in pulmonary embolism (PE).Patients diagnosed as having PE based on International Statistical Classification of Diseases and Related Health Problems, 10th Revision, German Modification code I26 in the German nationwide inpatient database were stratified for obesity, underweight, and normal weight/overweight (reference group) and compared regarding adverse in-hospital outcomes.From January 1, 2011, through December 31, 2014, 345,831 inpatients (53.3% females) 18 years and older were included in this analysis; 8.6% were obese and 0.5% were underweight. Obese patients were younger (67.0 vs 73.0 years), were mo…

Malemedicine.medical_specialtymedicine.medical_treatmentEmbolectomyOverweightThinnessInterquartile rangeInternal medicinemedicineHumansHospital MortalityObesitySurvival rateAgedAged 80 and overbusiness.industryMortality rateGeneral MedicineMiddle Agedmedicine.diseasePulmonary embolismSurvival RateFemalemedicine.symptomUnderweightbusinessPulmonary EmbolismBody mass indexMayo Clinic proceedings
researchProduct

Lemierre Syndrome: Clinical Update and Protocol for a Systematic Review and Individual Patient Data Meta-analysis.

2018

Lemierre syndrome usually affects otherwise healthy adolescents or young adults and occurs at an overall rate of 1 to 10 cases per million person-years with an estimated fatality rate of 4 to 9%. Diagnostic criteria remain debated and include acute neck/head bacterial infection (often tonsillitis caused by anaerobes at high potential for sepsis and vascular invasion, notably Fusobacterium necrophorum) complicated by local vein thrombosis, usually involving the internal jugular vein, and systemic septic embolism. Medical treatment is based on antibiotic therapy with anaerobic coverage, anticoagulant drugs and supportive care in case of sepsis. Surgical procedures can be required, including d…

AdultMalemedicine.medical_specialtyTonsillitisved/biology.organism_classification_rank.species030204 cardiovascular system & hematologySepsis03 medical and health sciencesYoung Adult0302 clinical medicineFusobacterium necrophorumJugular veinCase fatality ratemedicineHumansIntensive care medicine610 Medicine & healthInternal jugular veinSeptic embolismVenous Thrombosisbusiness.industryved/biologyAnticoagulantsHematologyLemierre Syndromemedicine.diseaseLemierre Study GroupPrognosisAnti-Bacterial AgentsVenous thrombosisFusobacterium necrophorumbusiness030215 immunologyHamostaseologie
researchProduct

Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition.

2021

Abstract Direct oral anti–activated factor X and antithrombin agents have largely replaced vitamin K antagonists as the standard of care in treatment of venous thromboembolism. However, gaps in efficacy and safety persist, notably in end‐stage renal disease, implantable heart valves or assist devices, extracorporeal support of the circulation, and antiphospholipid syndrome. Inhibition of coagulation factor XI (FXI) emerges as a promising new therapeutic target. Antisense oligonucleotides offer potential advantages as a prophylactic or therapeutic modality, with one dose‐finding trial in orthopedic surgery already published. In addition, monoclonal antibodies blocking activation and/or activ…

medicine.drug_class2720 Hematologyvenous thromboembolism610 Medicine & healthBioinformaticslaw.inventionchemistry.chemical_compoundRandomized controlled trialAntiphospholipid syndromelawAntithromboticMedicineDiseases of the blood and blood-forming organsFactor XIIbusiness.industrycatheter(s)Factor X10031 Clinic for AngiologyAntithrombinAnticoagulantanticoagulantHematologycontact systemmedicine.diseasefactor XIPulmonary embolismchemistryRC633-647.5businessState of the Art Isth 2020medicine.drugResearch and practice in thrombosis and haemostasis
researchProduct

Soluble Platelet Release Factors as Biomarkers for Cardiovascular Disease

2021

Platelets are the main players in thrombotic diseases, where activated platelets not only mediate thrombus formation but also are involved in multiple interactions with vascular cells, inflammatory components, and the coagulation system. Although in vitro reactivity of platelets provides information on the function of circulating platelets, it is not a full reflection of the in vivo activation state, which may be relevant for thrombotic risk assessment in various disease conditions. Therefore, studying release markers of activated platelets in plasma is of interest. While this type of study has been done for decades, there are several new discoveries that highlight the need for a critical a…

0301 basic medicineACUTE MYOCARDIAL-INFARCTIONVON-WILLEBRAND-FACTORDEEP VENOUS THROMBOSISvenous thromboembolismCD40 LIGANDContext (language use)ReviewDiseaseCardiovascular Medicinearterial thrombosis030204 cardiovascular system & hematologyBioinformatics03 medical and health sciences0302 clinical medicineVon Willebrand factorPERIPHERAL ARTERY-DISEASENONVALVULAR ATRIAL-FIBRILLATIONmedicineDiseases of the circulatory (Cardiovascular) systematrial fibrillationPlateletACUTE ISCHEMIC-STROKEMyocardial infarctionPlatelet activationThrombusthrombosisbiologybusiness.industryACUTE CORONARY SYNDROMESbiomarkersmedicine.diseaseThrombosisC-REACTIVE PROTEIN3. Good healthP-SELECTIN LEVELS030104 developmental biologyRC666-701plateletsbiology.proteinCardiology and Cardiovascular MedicinebusinessFrontiers in Cardiovascular Medicine
researchProduct

Definition of tachycardia for risk stratification of pulmonary embolism

2020

Tachycardia is a reliable predictor of adverse outcomes in normotensive patients with acute pulmonary embolism (PE). However, different prognostic relevant heart rate thresholds have been proposed. The aim of the study was to investigate the prognostic performance of different thresholds used for defining tachycardia in normotensive PE patients.We performed a post-hoc analysis of normotensive patients with confirmed PE consecutively included in a single-centre and a multi-centre registry. An adverse outcome was defined as PE-related death, need for mechanical ventilation, cardiopulmonary resuscitation or administration of catecholamines.Of 1567 patients (median age: 72 [IQR, 59-79] years; f…

Tachycardiamedicine.medical_specialtymedicine.medical_treatment030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciences0302 clinical medicineTachycardiaInternal medicineHeart rateInternal MedicineHumansMedicineIn patient030212 general & internal medicineCardiopulmonary resuscitationAgedMechanical ventilationbusiness.industryGuidelineMiddle AgedPrognosismedicine.diseasePulmonary embolismROC CurveRisk stratificationCardiologyFemalemedicine.symptomPulmonary EmbolismbusinessEuropean Journal of Internal Medicine
researchProduct

Ultrasound-Assisted Catheter-Directed Thrombolysis in High-Risk and Intermediate-High-Risk Pulmonary Embolism: Results From a Single-Center Cohort

2016

We present our single-center results on ultrasound-assisted thrombolysis (USAT) in patients with pulmonary embolism (PE) at intermediate high risk (IHR) and high risk (HR). Our study consisted of 75 patients with PE who underwent USAT (60 at IHR and 15 at HR). The median time delay from symptoms to USAT was 5 days. Ultrasound-assisted thrombolysis resulted in improvements in tricuspid annular plane systolic excursion; pulmonary artery (PA) systolic and mean pressures; Qanadli score; right to left ventricle diameter ratio and right to left atrial diameter ratio; and diameters of main, right, and left PA regardless of the baseline risk status ( P < .0001 for all). Death was documented in …

Malemedicine.medical_specialtyIohexolmedicine.medical_treatmentContrast Media030204 cardiovascular system & hematologySingle CenterCatheterization03 medical and health sciences0302 clinical medicineInternal medicinemedicine.arterymedicineHumansThrombolytic Therapy030212 general & internal medicineUltrasonography InterventionalRetrospective Studiesbusiness.industryRetrospective cohort studyThrombolysisMiddle Agedmedicine.diseasePulmonary embolismTreatment Outcomemedicine.anatomical_structureEchocardiographyVentricleCohortPulmonary arteryCardiologyFemaleIohexolPulmonary EmbolismTomography X-Ray ComputedCardiology and Cardiovascular Medicinebusinessmedicine.drugAngiology
researchProduct